BeiGene
BeiGene (Beijing) Co., Ltd. is a life sciences biotechnology company.
Launch date
Employees
Market cap
$22.0b
Enterprise valuation
$20.5b (Public information from Sep 2024)
Share price
$198.59 BGNE
Beijing China (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 309m | 1.2b | 1.4b | 2.5b | 3.6b | 4.5b | 5.6b |
| % growth | (28 %) | 281 % | 20 % | 74 % | 47 % | 25 % | 24 % |
| EBITDA | (1.7b) | (1.4b) | (1.8b) | (1.1b) | (588m) | (93.2m) | 440m |
| % EBITDA margin | (536 %) | (122 %) | (126 %) | (46 %) | (16 %) | (2 %) | 8 % |
| Profit | (1.6b) | (1.4b) | (2.0b) | (882m) | (683m) | (168m) | 371m |
| % profit margin | (517 %) | (120 %) | (142 %) | (36 %) | (19 %) | (4 %) | 7 % |
| EV / revenue | 62.7x | 20.5x | 13.8x | 6.7x | 5.2x | 4.1x | 3.3x |
| EV / EBITDA | -11.7x | -16.8x | -10.9x | -14.8x | -31.7x | -201.2x | 41.5x |
| R&D budget | 1.3b | 1.5b | 1.6b | 1.8b | - | - | - |
| R&D % of revenue | 419 % | 124 % | 116 % | 72 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$75.0m | Series A | ||
$96.6m | Series B | ||
| N/A | N/A | IPO | |
| N/A | $185m | Post IPO Equity | |
| N/A | $750m | Post IPO Equity | |
| N/A | $903m | Secondary | |
$2.8b | Post IPO Equity | ||
| Total Funding | $172m | ||
Related Content
Recent News about BeiGene
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
